p-Bromo Aniline | CAS:106-40-1

We serve p-Bromo Aniline CAS:106-40-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
p-Bromo Aniline

Chemical Name: p-Bromo Aniline
CAS: 106-40-1
Synonyms:
para-bromoaniline
4-Bromoaniline
Benzenamine,4-bromo
 
Molecular formula C6H6BrN
Molecular weight 172.02434
pH 3.7-4.0
Melting point 60-64°C
Boiling point 230-250 ° C
Flash point >110°C
Decomposition temperature >230°C
Solubility < 0.1 g / 100 ml in water
Relative density 1.497
 
Specification:
Appearance: Ash-brown powder crystal
Assay: 99.0%min
Moisture: ≤0.5%
 
Application: for azo dye manufacturing and organic synthesis.



Contact us for information like p-Bromo Aniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Benzenamine,4-bromo physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,p-Bromo Aniline Use and application,p-Bromo Aniline technical grade,usp/ep/jp grade.


Related News: Hong Kong confirmed its 14th coronavirus case late Saturday. The patient, an 80-year-old man, had traveled for a few hours to mainland China in early January, and later spent several days on a cruise ship in Japan with more than 3,000 passengers and employees.prop-2-yn-1-ol manufacturer Hong Kong confirmed its 14th coronavirus case late Saturday. The patient, an 80-year-old man, had traveled for a few hours to mainland China in early January, and later spent several days on a cruise ship in Japan with more than 3,000 passengers and employees.1-Bromo-4-phenylbutan-2-one supplier In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.Hexyl nicotinoate vendor In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.According to statistics, in the ten years from 2008 to 2017, a total of 13 “China Class 1” small-molecule chemical drugs were independently researched and developed by domestic enterprises in China and approved by the CFDA; in 2018, there were 10 varieties of domestic Class 1 new drugs. Approved for listing in China.